多西他赛+奥沙利铂+替吉奥与多西他赛+顺铂+氟尿嘧啶方案治疗晚期胃癌的对比研究被引量：32

Effects comparison of docetaxel in combination with oxaliplatin + S-1 and docetaxel in combination with cisplatin + fluorouracil on advanced gastric cancer

下载PDF

导出

摘要目的:比较多西他赛+奥沙利铂+替吉奥与多西他赛+顺铂+氟尿嘧啶方案治疗晚期胃癌的预后情况及血清指标。方法:选择在我院接受化疗的496例晚期胃癌患者,随机分为DSOX组(多西他赛+奥沙利铂+替吉奥组)和DCF组(多西他赛+顺铂+氟尿嘧啶组),随访无进展生存时间(PFS)以及总生存时间(OS);化疗前和化疗后2个周期时,采集血清并测定ALT、AST、BUN、CR、CRP、CEA、CA19-9、CA72-4、VEGF、IGF-1、MMP2、MMP7、MMP9的含量。结果:DSOX组中位PFS和中位OS均长于DCF组;化疗后,两组血清ALT、AST、BUN、CR、CRP含量均高于化疗前(P<0.05);且两组间的血清ALT、AST、BUN、CR、CRP含量无差异(P>0.05);化疗后,两组血清中CEA、CA19-9、CA72-4、VEGF、IGF-1、MMP2、MMP7、MMP9的含量均显著低于化疗前(P<0.05);且DSOX组患者化疗后血清中CEA、CA19-9、CA72-4、VEGF、IGF-1、MMP2、MMP7、MMP9的含量显著低于DCF组(P<0.05)。结论:DSOX化疗方案能够延长晚期胃癌患者的无进展生存时间及总生存时间且对癌细胞的杀伤效果、对胃癌组织中血管新生以及癌细胞侵袭的抑制效果优于DCF方案。 [ABSTRACT]Objective：To compare the prognosis and serum indexes after treatment of docetaxel in combination with ox-aliplatin ＋ S-1 or docetaxel in combination with cisplatin ＋ fluorouracil on advanced gastric cancer.Methods：A total of 496 patients with advanced gastric cancer who received chemotherapy in our hospital were selected and randomly divided into DSOX group （docetaxel ＋ oxaliplatin ＋ S-1 group）and DCF model group （docetaxel ＋ cisplatin ＋ fluorouracil group）,and the progression-free survival （PFS）and overall survival （OS）were followed up;before chemotherapy and after two cycles of chemotherapy,serum was collected to determine ALT,AST,BUN,CR,CRP,CEA,CA1 9-9,CA72-4,VEGF,IGF-1, MMP2,MMP7 and MMP9 levels.Results：Median PFS and median OS of DSOX group were longer than those of DCF group;after chemotherapy,serum ALT,AST,BUN,CR and CRP levels of both groups were higher than those before chemotherapynbsp;（P 〈0.05 ）but difference in serum ALT,AST,BUN,CR and CRP levels between two groups were not significant （P 〉0.05）;after chemotherapy,serum CEA,CA1 9-9,CA72-4,VEGF,IGF-1,MMP2,MMP7 and MMP9 levels of both groups were significantly lower than those before chemotherapy （P 〈 0.05 ）and serum CEA,CA1 9-9,CA72-4,VEGF,IGF-1, MMP2,MMP7 and MMP9 levels of DSOX group were significantly lower than those of DCF group （P 〈0.05 ）.Conclusion：DSOX chemotherapy can prolong progression-free survival and overall survival in patients with advanced gastric cancer and has better killing effect on cancer cells and better inhibiting effect on angiogenesis in gastric cancer tissue and cancer cell invasion than DCF chemotherapy.

作者李玮赵鹏

机构地区陕西省汉中市中心医院药剂科陕西省汉中市

出处《海南医学院学报》 CAS 2016年第17期2015-2018,共4页 Journal of Hainan Medical University

基金中航工业(3201yk201605)~~

关键词晚期胃癌无进展生存时间总生存时间肿瘤标志物血管新生侵袭 Advanced gastric cancer Progression-free survival Overall survival Tumor markers Angiogenesis In-vasion

分类号 R735.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献18

1John C. Layke,Peter P. Lopez.胃癌：诊断和治疗方案的选择[J].中国全科医学,2015,18(3):248-249. 被引量：56
2Shah MA,Janjigian YY,Stoller R,et al.Randomized Multicenter Phase II Study of Modified Docetaxel,Cisplatin,and Fluorouracil(DCF)Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma:A Study of the US Gastric Cancer Consortium[J].J Clin Oncol,2015,33(33):3874-3879.
3Feng ZL,Chen LB,Liu ZY,et al.DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer:A feasibility study[J].Oncol Lett,2015,9(1):491-497.
4Van Cutsem E,Boni C,Tabernero J,et al.Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer:a randomized phase II study[J].Ann Oncol,2015,26(1):149-156.
5Teker F,Yilmaz B,Kemal Y,et al.Efficacy and safety of docetaxel or epirubicin,combined with cisplatin and fluorouracil(DCF and ECF),regimens as first line chemotherapy for advanced gastric cancer:a retrospective analysis from Turkey[J].Asian Pac J Cancer Prev,2014,15(16):6727-6732.
6Dong L,Li J,Lou XP,et al.Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer[J].J Int Med Res,2014,42(3):737-743.
7Liu Y,Feng Y,Gao Y,et al.Clinical benefits of combined chemotherapy with S-1,oxaliplatin,and docetaxel in advanced gastric cancer patients with palliative surgery[J].Onco Targets Ther,2016,7(9):1269-1273.
8Guo M,Yu Y,Wang Y,et al.Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma[J].Med Oncol,2015,32(9):230.
9Kim HS,Ryu MH,Zang DY,et al.Phase II study of docetaxel,oxaliplatin,and S-1therapy in patients with metastatic gastric cancer[J].Gastric Cancer,2016,19(2):579-585.
10Wang M,Wu M,Wang W,et al.Docetexal plus S-1versus oxaliplatin plus S-1for first-line treatment of patients with advanced gastric cancer:a retrospective study[J].Oncol Res Treat,2014,37(1-2):24-28.

二级参考文献53

1唐丽,郑小华.三种肿瘤标志物联合检测胃癌的互补诊断价值[J].内蒙古医科大学学报,2012,34(S2):209-210. 被引量：1
2吴毅平,Shoshana Yakar,Derek LeRoith.循环中胰岛素样生长因子-Ⅰ水平调节结肠癌的生长和转移研究[J].中华实验外科杂志,2004,21(5):598-601. 被引量：10
3Ling Yang.Incidence and mortality of gastric cancer in China[J].World Journal of Gastroenterology,2006,12(1):17-20. 被引量：345
4刘复生.中国肿瘤病理学分类[M].北京：科学技术文献出版社,2001.225-226.
5Ubukata H, Katano M, Motohashi G, et al. Evaluation of CA72-4 as a tumor marker in patients with gastric cancer [J]. Cancer Res Clin Oncol, 2003,30( 11 ) : 1821-1824.
6Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer [J]. EJSO,2005,31(2) : 164-169.
7Ucar E, Semerci E, Ustun H, et al. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer[J]. Adv Ther, 2008,25 (10) : 1075-1084.
8朱汉民,沈霞.临床实验诊断学[M].上海:上海科学技术出版卡t,2004:918-934.
9Chen XZ, Zhang WK, Yang K. Correlation between serum CA72-4 and gastric cancer: multiple analyses based on Chinese population [J]. Mol Biol Rep,2012,39(9) :9031-9039.
10Lai IR, Lee WJ, Huang MT, et al. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence[J]. Hepatogastroenterology,2002, 49(46) : 1157-1160.